Get the Stockscreener App
2.51
2.03%
0.05
Kalaris Therapeutics Inc stock is traded at $2.51, with a volume of 67,709.
It is up +2.03% in the last 24 hours and down -2.33% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$2.46
Open:
$2.58
24h Volume:
67,709
Relative Volume:
1.38
Market Cap:
$46.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.03%
1M Performance:
-2.33%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.37
$2.58
1-Week Range:
$2.36
$2.64
52-Week Range:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
628 MIDDLEFIELD ROAD, PALO ALTO
Compare KLRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
2.51 | 46.76M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Using data filters to optimize entry into Kalaris Therapeutics Inc.July 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Can Kalaris Therapeutics Inc. hit a new high this monthPortfolio Gains Report & Risk Controlled Stock Pick Alerts - Newser
What’s the recovery path for long term holders of Kalaris Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - Newser
Is it time to cut losses on Kalaris Therapeutics Inc.Dip Buying & Free Reliable Trade Execution Plans - Newser
Using AI based signals to follow Kalaris Therapeutics Inc.2025 Stock Rankings & Community Consensus Stock Picks - Newser
Can a trend reversal in Kalaris Therapeutics Inc. lead to recoveryJuly 2025 Recap & AI Powered Market Trend Analysis - Newser
Market reaction to Kalaris Therapeutics Inc.’s recent news2025 Top Decliners & Intraday High Probability Alerts - Newser
Key metrics from Kalaris Therapeutics Inc.’s quarterly dataJuly 2025 Earnings & Verified High Yield Trade Plans - Newser
Kalaris Therapeutics Inc. stock trendline breakdownWeekly Trade Review & Trade Opportunity Analysis Reports - Newser
Using R and stats models for Kalaris Therapeutics Inc. forecastingMarket Performance Report & Real-Time Buy Zone Alerts - Newser
Understanding Kalaris Therapeutics Inc.’s price movementTrade Volume Summary & Growth Focused Investment Plans - Newser
Published on: 2025-08-19 04:17:46 - Newser
Will Kalaris Therapeutics Inc. stock go up soonFed Meeting & Advanced Technical Analysis Signals - Newser
Kalaris Therapeutics Inc. Shows Early Signs of Technical Strength2025 Market Outlook & AI Powered Market Trend Analysis - beatles.ru
Kalaris Therapeutics Inc. Breakout Confirmed by Volume MetricsJuly 2025 Momentum & Weekly Sector Rotation Insights - newsimpact.co.kr
Is Kalaris Therapeutics Inc. stock entering bullish territoryTreasury Yields & Stepwise Trade Signal Guides - Newser
Should I buy Kalaris Therapeutics Inc. stock before earningsJuly 2025 Intraday Action & AI Powered Buy and Sell Recommendations - Newser
Is Kalaris Therapeutics Inc. stock a good hedge against inflationM&A Rumor & Consistent Growth Stock Picks - Newser
Will earnings trigger a reversal in Kalaris Therapeutics Inc.2025 Technical Patterns & Free Fast Entry Momentum Trade Alerts - Newser
Multi asset correlation models including Kalaris Therapeutics Inc.Portfolio Return Report & AI Powered Trade Plan Recommendations - Newser
Has Kalaris Therapeutics Inc. formed a bullish divergenceJuly 2025 Highlights & Daily Stock Trend Watchlist - Newser
Using Ichimoku Cloud for Kalaris Therapeutics Inc. technicalsJuly 2025 Review & Safe Capital Investment Plans - Newser
Leerink Partners Maintains Kalaris Therapeutics(KLRS.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):